The Chief Executive Officer of Pune based Serum Institute of India, Adar Poonawalla has stated that his institute is conducting the phase 3 trial of Oxford-Astrazeneca Covid 19 vaccine in India and it should be ready for public use by December. The Serum Institute will apply for an emergency license from the Indian regulator.
The 39 year old CEO went on to say that there were no immediate concerns about the safety of the vaccine as early indicators have been positive. It will be a two dose vaccine with a 28 day gap between the two doses. The price of the vaccine will be affordable as the government will take most of the load. Out of more than 150 vaccines being developed and tested globally, it is anticipated that the Oxford vaccine will be one of the first to secure regulatory approval.